Featured Publications
The Zero Suicide Model in Addiction Treatment Settings: Recognizing the Need for Feasibility and Implementation Data
Arakelian M, Barnett B, Weleff J. The Zero Suicide Model in Addiction Treatment Settings: Recognizing the Need for Feasibility and Implementation Data. Psychiatric Services 2023, 75: 378-380. PMID: 37933133, DOI: 10.1176/appi.ps.20230175.Peer-Reviewed Original ResearchConceptsAddiction treatment settingsTreatment settingsZero SuicideSubstance use disordersZero Suicide modelAddiction outcomesUse disorderSuicide modelsAddiction treatmentHealth care settingsAddictionHealth care systemSuicide preventionSuicideImplement best practicesCare settingsCare systemOpen ForumIncreased riskBest practicesHealthDisordersSetsResearchClinicians
2024
Psychotherapeutic Interventions in Clinical Trials of Psychedelics for the Treatment of Alcohol Use Disorder
Mohammad Aghaei A, Weleff J, Martins B, Ing K, Fontenele R, Barnett B, Anand A, Bassir Nia A. Psychotherapeutic Interventions in Clinical Trials of Psychedelics for the Treatment of Alcohol Use Disorder. Current Addiction Reports 2024, 11: 685-712. DOI: 10.1007/s40429-024-00574-y.Peer-Reviewed Original ResearchTreatment of AUDUse disorderTreatment of alcohol use disordersModalities of psychotherapyAlcohol use disorderPsychedelic treatmentPsychotherapeutic interventionsTreat AUDPsychedelic compoundsPsychedelic trialsPsychotherapySmall numbers of participantsPsychedelicsMagnitude of improvementMethodological shortcomingsAUDNumbers of participantsClinical trialsDisordersReviewed trialsShort follow-up periodFollow-up periodTherapy methodsEmpirical evidenceNo significant difference
2023
Cognitive, imaging, and psychiatric changes associated with chronic toluene use: case report and literature review
Jupina M, Weleff J, Harp J, Anand A. Cognitive, imaging, and psychiatric changes associated with chronic toluene use: case report and literature review. Journal Of Addictive Diseases 2023, 42: 556-566. PMID: 37503800, DOI: 10.1080/10550887.2023.2229735.Peer-Reviewed Original ResearchInhalant use disorderUse disorderToluene misuseEvidence-based treatmentsFlat affectVisuospatial functionNeurocognitive deficitsComplex cognitionPsychiatric consequencesPsychiatric deficitsPsychiatric effectsWhite matter changesEffects of tolueneMisuse inhalantsImpact adolescentsDeficitsMatter changesDisordersCognitionInhaler misuseLoss of gray-white matter differentiationDiffuse white matter changesGray-white matter differentiationMisuseCorpus callosum thinning
2022
Treatment of Misophonia with Risperidone in a Patient with Autism Spectrum Disorder
Pan E, Weleff J, Anand A, Barnett B. Treatment of Misophonia with Risperidone in a Patient with Autism Spectrum Disorder. Case Reports In Psychiatry 2022, 2022: 3169834. PMID: 36247223, PMCID: PMC9553690, DOI: 10.1155/2022/3169834.Peer-Reviewed Original ResearchAutism spectrum disorderSpectrum disorderTreatment of misophoniaSimultaneous pharmacologic treatmentsTreat misophoniaScale-RevisedRisperidoneDecreased irritabilityMisophoniaPharmacological treatmentAutismImproved behaviorDisordersInpatient admissionsSymptomatic improvementFollow-up findingsSymptomsTreatmentScoresManagement of Phenibut Use Disorder and Withdrawal in a Geriatric Patient
Wainblat E, Weleff J, Anand A. Management of Phenibut Use Disorder and Withdrawal in a Geriatric Patient. American Journal Of Geriatric Psychiatry 2022, 31: 67-74. PMID: 36266201, DOI: 10.1016/j.jagp.2022.09.008.Peer-Reviewed Original ResearchConceptsUse disorderAlcohol use disorderAnxiolytic use disorderWorsen affective disordersAffective disordersPhysiological dependenceMisuse substancesNootropic propertiesWithdrawal managementAlleviate anxietyFood and Drug AdministrationDisordersPhenibutWithdrawalAddictionClinical effectsGeriatric patientsDrug AdministrationGeriatric populationDrug profileAlcoholAnxietyBenzodiazepinesAnxiolysisInsomniaPsychedelics in the Treatment of Substance Use Disorders
Barnett B, Weleff J. Psychedelics in the Treatment of Substance Use Disorders. Psychiatric Annals 2022, 52: 365-370. DOI: 10.3928/00485713-20220804-01.Peer-Reviewed Original ResearchSubstance use disordersPsychedelic experienceTreatment of substance use disordersLysergic acid diethylamideSubjective effectsUse disorderAcid diethylamidePlacebo-controlled trialPsychedelicsBehavioral changesTherapeutic potentialClinician concernsLife narrativesDisordersFacilitation programTreatment paradigmTherapeutic efficacyClinical trialsTreatment potentialObservational studyPsilocybinDiethylamideTrialsSubstancesOpioid